For pediatric patients with T-cell origin lymphoblastic leukemia (T-LBL) with disease progression following second-line treatment, investigators found that the JAK1/2 pathway may be a new actionable ...

Patients with myelofibrosis who were treated with Janus-kinase (JAK) 1/2 inhibitors have an increased risk for developing B-cell lymphoma. However, researchers believe there is a pre-existing B-cell ...

Drugs that target the Janus-kinase 1/2 (JAK1/2) pathway have become a mainstay of treatment for myeloproliferative neoplasms (MPNs), but new research suggests that their use may be associated with an ...

Monitoring early clearance of circulating tumor DNA as an effective tool to predict clinical benefits of immune checkpoint inhibitors in lung cancer patients: The preliminary results from clinical ...

The chronic myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The most frequent clinical complications of ET and PV ...

Treatment with a novel, oral JAK1 tyrosine kinase inhibitor induced rapid and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), findings from a single-arm ...

Researchers suggest anticancer kinase inhibitor candidates may have additional immunological effects in vivo. Researchers have demonstrated that silencing the JAK1 and JAK 2 genes in cancer cells ...

Janus kinase (JAK1/2) inhibitors have been useful in treating myeloproliferative neoplasms (MPN) since the pathway was first recognized to be critical to malignancy development in the 1990s. A new ...

YM BioSciences Inc. has announced the pre-publication of pivotal preclinical data for CYT387, the company’s highly selective and potent JAK1/2 inhibitor, currently in a Phase I/II trial for ...